Beta Bionics (NASDAQ:BBNX) Releases Earnings Results, Misses Estimates By $1.40 EPS

Beta Bionics (NASDAQ:BBNX) released its quarterly earnings results on Tuesday. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.42) by ($1.40), Zacks reports. Beta Bionics updated its FY 2025 guidance to EPS.

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded up $0.37 during trading on Tuesday, hitting $15.22. 416,841 shares of the company were exchanged, compared to its average volume of 458,405. Beta Bionics has a 1-year low of $13.64 and a 1-year high of $24.50.

Analyst Upgrades and Downgrades

BBNX has been the topic of a number of recent research reports. Leerink Partnrs upgraded Beta Bionics to a “strong-buy” rating in a research report on Monday, February 24th. Bank of America assumed coverage on Beta Bionics in a report on Monday, February 24th. They issued a “buy” rating on the stock. Leerink Partners began coverage on Beta Bionics in a research report on Monday, February 24th. They issued an “outperform” rating and a $28.00 price objective for the company. Robert W. Baird began coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price on the stock. Finally, Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.83.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger bought 33,350 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. The trade was a 129.92 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.